Chiesi outperforming, with sales rising over three times industry average

Italian drugmaker Chiesi’s commitment to innovation and scientific collaboration continues to deliver positive results for the company, despite a challenging environment for the pharmaceutical industry dominated by price cuts, reimbursement issues and a general decline in pipeline products. The company’s impressive track record of double-digit growth continued through 2010 with a 16.4% increase in revenue, which is over three times the industry growth rate and sales exceeding 1 billion euros ($1.35 billion).

The firm’s chief executive, Alberto Chiesi, comments: “We are passionate about bringing therapies to market where there is an ongoing requirement to meet patients’ healthcare needs. We firmly believe that our positive results are owed to an unwavering commitment to and nurturing of innovation as the optimal route to discovering new, state-of-the-art therapies, which will make a genuine positive impact on people’s lives.”

Chiesi’s clinical pipeline predominantly includes projects designed to make significant advances in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in order to contribute to improving the quality of life of patients affected by these conditions. However, the company is also involved in developing therapies for use in intensive care for premature newborns and cardiovascular disease as well as cystic fibrosis, regenerative medicine and Alzheimer’s disease. The preclinical pipeline includes further respiratory compounds including both anti-inflammatory and bronchodilating agents.